Researchers at Mass General Brigham found that a nasal spray delivering anti-CD3 (Foralumab) reduces neuroinflammation, limits central nervous system damage and improves behavioral outcomes in mice ...

Intranasal foralumab, developed by biotech company ... million grant from the National Institute on Aging to study the nasal spray for Alzheimer’s, just a few months after the FDA approved ...

The randomized, double-blind, placebo-controlled trial is assessing the safety, tolerability, and efficacy of intranasal foralumab ... through its innovative nasal delivery technology.

Foralumab, a nasal spray originally developed to treat multiple sclerosis and used by MGB physicians for Alzheimer’s treatment under FDA compassionate use protocols, was tested in mouse models ...

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...

The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of ...

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial Tiziana Life Sciences Ltd. Wed, Apr 2, 2025, 8:00 AM 5 min read ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in ... Tiziana’s innovative nasal approach has the potential ...